Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes
10.1016/j.jacc.2021.04.079
Saved in:
Main Authors: | Filippatos, Gerasimos, Bakris, George L., Pitt, Bertram, Agarwal, Rajiv, Rossing, Peter, Ruilope, Luis M., Butler, Javed, Lam, Carolyn S. P., Kolkhof, Peter, Roberts, Luke, Tasto, Christoph, Joseph, Amer, Anker, Stefan D., FIDELIO-DKD Investigators. |
---|---|
Other Authors: | DUKE-NUS MEDICAL SCHOOL |
Format: | Article |
Published: |
Elsevier Inc.
2022
|
Subjects: | |
Online Access: | https://scholarbank.nus.edu.sg/handle/10635/232604 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | National University of Singapore |
Similar Items
-
Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial
by: Bakris, George L, et al.
Published: (2023) -
Finerenone and Chronic Kidney Disease Outcomes in Type 2 Diabetes
by: George L. Bakris, et al.
Published: (2022) -
Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes
by: Pitt, Bertram, et al.
Published: (2023) -
Lone atrial fibrillation: Influence of familial disease on gender predilection
by: Chen, L.Y., et al.
Published: (2014) -
An updated meta-analysis on the clinical outcomes of percutaneous left atrial appendage closure versus direct oral anticoagulation in patients with atrial fibrillation
by: Jiang, Haowen, et al.
Published: (2023)